By Sheeba M. | April 30, 2026
Federal Rescheduling Timeline: What Schedule III Means for Investors
The betting markets are shifting. Congressional momentum on cannabis rescheduling has accelerated to levels unseen since 2021. Multiple sources inside the DEA and Treasury Department suggest a Schedule III petition could advance to final rule by Q4 2026—potentially triggering one of the largest equity revaluations in financial markets.
Schedule III vs Schedule I: The Structural Break
Currently, cannabis is Schedule I (no medical use, high abuse potential). Moving to Schedule III (medical applications, lower abuse potential) fundamentally changes market access:
- Banks can serve cannabis businesses without federal Money Laundering Control Act exposure
- Institutional investors can hold cannabis equity without reputational risk
- MSOs can refinance at institutional rates (not 15% penalty rates)
- Pharmacy chains can negotiate CBD-dominant product distribution
Current market cap for large MSOs: $45B total. If Schedule III approval removes the “illicit business” stigma, comparable consumer staples multiples (12-14x EBITDA) could apply. That’s a 40-50% valuation pop.
The Banking Multiplier Effect
Cannabis operators are currently forced to hold 60-70% of cash on-hand due to banking restrictions. This cash drag suppresses profitability metrics and makes refinancing impossible. When banking normalizes post-rescheduling:
- Curaleaf (CURLF): Estimated $800M in working capital freed up → EBITDA margin expansion of 8-12 percentage points
- Trulieve (TCNNF): $600M working capital relief → Cash flow inflection
- Greengro (GTBIF): $200M+ in Mexico expansion capital becomes accessible for the first time
This isn’t speculative. Every basis point of improved cash conversion cycles directly flows to earnings. Institutions are pre-positioning.
Timing Risk: The 2026 Window
Congressional action must happen before Q1 2027 (midterms pressure + legislative calendar). If rescheduling stalls past 2026, valuations could correct 20-30% as institutional investors reassess long-term policy risk. The window is real and finite.
Sources
- Congress.gov SAFER Act — Status and co-sponsors
- DEA Drug Scheduling — Official scheduling framework
- SEC EDGAR — MSO cash position disclosures
Track cannabis stocks with the Weedstock Real-Time Tracker